Bundelkhand Online Journal

90+ Leading Prostate Cancer Pipeline Companies are working to improve the Treatment Landscape

 Breaking News
  • No posts were found

90+ Leading Prostate Cancer Pipeline Companies are working to improve the Treatment Landscape

February 27
10:20 2023
90+ Leading Prostate Cancer Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insights, 2023” report provides comprehensive insights about 90+ companies and 110+ pipeline drugs in the metastatic prostate cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including Metastatic Prostate Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Metastatic Prostate Cancer emerging drugs, the Metastatic Prostate Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Metastatic Prostate Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Metastatic Prostate Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Metastatic Prostate Cancer clinical trials studies, Metastatic Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Metastatic Prostate Cancer Pipeline Report

 

  • Over 90+ Metastatic Prostate Cancer companies are evaluating 110+ Metastatic Prostate Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Prostate Cancer market would significantly increase market revenue.

 

  • The leading Metastatic Prostate Cancer Companies includes Zenith Epigenetics, WntResearch, Veru Inc.,  VasGene Therapeutics, ValiRx, Vaccitech, Ultimovacs ASA, Trovagene, Tracon, Tmunity Therapeutics, Tesaro, and others.

 

  • Promising Metastatic Prostate Cancer Pipeline Therapies includes Enzalutamide, Sunitinib, Metformin, Anti-OX40, Cyclophosphamide, Cabazitaxel, and others.

 

  • The Metastatic Prostate Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Prostate Cancer R&D. The Metastatic Prostate Cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Prostate Cancer.

  

To explore more information on the latest breakthroughs in the Metastatic Prostate Cancer Pipeline treatment landscape of the report, click here @ Metastatic Prostate Cancer Pipeline Outlook

 

Metastatic Prostate Cancer Overview

Metastatic Prostate Cancer is a type of prostate cancer which spreads to the other parts of body, i.e., cancer has “metastasized.” Most often, prostate cancer spreads to the bones or lymph nodes. It’s also common for it to spread to the liver or lungs. It’s rarer for it to move to other organs, such as the brain. Metastatic prostate cancer is an advanced form of cancer. There’s no cure, but it can treat it and control it. Most men with advanced prostate cancer live a normal life for many years.

 

Latest Developmental Activities in the Metastatic Prostate Cancer Treatment Landscape

 

  • Roche is investigating ipatasertib as part of a combination with Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) in asymptomatic or mildly symptomatic, previously untreated metastatic castration-resistant prostate cancer patients.

 

  • DCVAC is an autologous immunotherapy manufactured from a patient’s white blood cells. It is composed of autologous Polyinosinic-Polycytidylic activated dendritic cells pulsed with killed LNCaP prostate cancer cell line. Sotio is currently leading following trials for the treatment of Metastatic prostate cancer.

 

For further information, refer to the detailed Metastatic Prostate Cancer Unmet Needs, Metastatic Prostate Cancer Market Drivers, and Metastatic Prostate Cancer Market Barriers, click here for Metastatic Prostate Cancer Ongoing Clinical Trial Analysis

 

Metastatic Prostate Cancer Emerging Drugs Profile

 

  • FP-001: Foresee Pharmaceuticals

FP-001 is a long-acting gonadotropin releasing hormone (GnRH) agonist being developed as Leuprolide Mesylate for Injectable Suspension. It is under development by Foresee Pharmaceuticals and ScinoPharm Joint Venture and is currently in Phase III stage for the treatment of Prostate Cancer. The drug candidate is being developed in different dosage formulations and depending on them, they are in different stages of development.

 

  • Relugolix: Myovant Biosciences

Relugolix (Pre-registration) is the Myovant’s lead product candidate and is an orally available small molecule, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH).

 

  • Atezolizumab: Genentech

Atezolizumab (Tecentriq, Phase III) is a novel, anti-PDL1 targeted prescription cancer immunotherapy. It is monoclonal antibody derived from the Chinese hamster ovary cells by recombinant DNA technology. Atezolizumab works by binding to PD-L1 receptor expressed on tumor cells and tumor-infiltrating immune cells and thereby leads to the prevention of binding of PD-L1 receptor to other proteins namely as B7.1 and PD-1. This process leads to the release of PD-1/ PD-L1 mediated inhibition of the immune response, and also causes the activation of anti-tumor immune response without inducing the antibody dependent cellular cytotoxicity (ADCC). As stated by the company, this mode of action may eliminate the “stop sign” that gives the signals to inactivate T-cells. Tecentriq may also affect normal cells. 

 

  • Darolutamide: Bayer

Darolutamide (Phase III) is an orally administered second generation androgen receptor (AR) antagonist that has a unique chemical structure designed to block the growth of cancer cells through binding to the AR with high affinity and inhibiting the receptor function. In preclinical studies, darolutamide and its main circulating metabolite are active also in known AR mutants (ex W742L, F877L), and have been found to have negligible blood-brain barrier penetration.

 

  • DCVAC/PCa: Sotio

DCVAC is an autologous immunotherapy manufactured from a patient’s white blood cells. It is composed of autologous Polyinosinic-Polycytidylic activated dendritic cells pulsed with killed LNCaP prostate cancer cell line. Sotio is currently leading following trials for the treatment of Metastatic prostate cancer-

 

Phase III: Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

 

Phase I/II: Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men with Advanced Metastatic Castration-resistant Prostate Cancer

 

  • Ipatasertib: Roche

Ipatasertib is an orally administered small molecule, potent, novel, selective ATP-competitive, selective AKT inhibitor which is designed to target and bind to the adenosine triphosphate (ATP)-binding pocket of the 3 activated isoforms of AKT, potentially inhibiting downstream signaling. Ipatasertib is being investigated in combination with various treatment modalities (e.g., anti-hormonal therapy, chemotherapy). It acts as serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Currently, Roche is investigating ipatasertib as part of a combination with Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) in asymptomatic or mildly symptomatic, previously untreated metastatic castration-resistant prostate cancer patients.

 

Metastatic Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. Pre-registration phase include, Foresee Pharmaceuticals and Myovant Biosciences.

 

Request a sample and discover the recent advances in Metastatic Prostate Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Prostate Cancer Treatment Landscape

 

Scope of the Metastatic Prostate Cancer Pipeline Report

 

  • Coverage- Global

 

  • Metastatic Prostate Cancer Companies- Zenith Epigenetics, WntResearch, Veru Inc.,  VasGene Therapeutics, ValiRx, Vaccitech, Ultimovacs ASA, Trovagene, Tracon, Tmunity Therapeutics, Tesaro, and others.

 

  • Metastatic Prostate Cancer Pipeline Therapies- Enzalutamide, Sunitinib, Metformin, Anti-OX40, Cyclophosphamide, Cabazitaxel, and others.

 

  • Metastatic Prostate Cancer Pipeline Therapies- Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Metastatic Prostate Cancer Market Drivers and S Metastatic Prostate Cancer Market Barriers, click here @ Metastatic Prostate Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Prostate Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Metastatic Prostate Cancer Collaboration Deals
  9. Late Stage Products
  10. Atezolizumab: Genentech
  11. Darolutamide: Bayer
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products
  14. Recombinant EphB4-HSA Fusion Protein: Vasgene Therapeutics
  15. AZD4635: AstraZeneca PLC
  16. Drug profiles in the detailed report…..
  17. Early Stage Products
  18. Gallium-68-P16 093: Five Eleven Pharma
  19. ABBV-744: Abbvie
  20. Drug profiles in the detailed report…..
  21. Pre-clinical and Discovery Stage Products
  22. EPI 7386: ESSA Pharma
  23. Drug profiles in the detailed report…..
  24. Inactive Products
  25. Metastatic Prostate Cancer Key Companies
  26. Metastatic Prostate Cancer Key Products
  27. Metastatic Prostate Cancer- Unmet Needs
  28. Metastatic Prostate Cancer- Market Drivers and Barriers
  29. Metastatic Prostate Cancer- Future Perspectives and Conclusion
  30. Metastatic Prostate Cancer Analyst Views
  31. Metastatic Prostate Cancer Key Companies
  32. Appendix

 

Got Queries? Find out the related information on Metastatic Prostate Cancer Mergers and acquisitions, Metastatic Prostate Cancer Licensing Activities @ Metastatic Prostate Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services